• Can-Fite reported ten-year survival for an advanced liver cancer patient in its completed Phase II Namodenoson study; she remains cancer-free.
• The patient's complete response was previously reported; the latest update follows the nine-year survival announcement in November 2025.
• Namodenoson remains in a pivotal Phase III trial for advanced liver cancer patients with underlying cirrhosis.
• Longer-than-expected survival across treatment and placebo groups prompted consideration of an earlier interim analysis, as announced September 2, 2026.
• The trial remains blinded; treatment-specific efficacy results will be assessed in the planned analysis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Can Fite Biofpharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611090700PRIMZONEFULLFEED9873152) on November 09, 2026, and is solely responsible for the information contained therein.